1
|
Seervai RNH, Cho WC, Chu EY, Marques-Piubelli ML, Ledesma DA, Richards K, Heberton MM, Nelson KC, Nagarajan P, Torres-Cabala CA, Prieto VG, Curry JL. Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. J Cutan Pathol 2021; 49:61-81. [PMID: 34622477 DOI: 10.1111/cup.14145] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 08/29/2021] [Accepted: 10/02/2021] [Indexed: 12/12/2022]
Abstract
BACKGROUND Advances in molecular biology and genetics have contributed to breakthrough treatments directed at specific pathways associated with the development of cancer. Small-molecule inhibitors (Nibs) aimed at a variety of cellular pathways have been efficacious; however, they are associated with significant dermatologic toxicities. METHODS We conducted a comprehensive review of dermatologic toxicities associated with Nibs categorized into the following five groups: (a) mitogen-activated protein kinase; (b) growth factor/multi-tyrosine kinase; (c) cell division/DNA repair; (d) signaling associated with myeloproliferative neoplasms; and (e) other signaling pathways. Prospective phase I, II, or III clinical trials, retrospective literature reviews, systematic reviews/meta-analyses, and case reviews/reports were included for analysis. RESULTS Dermatologic toxicities reviewed were associated with every class of Nibs and ranged from mild to severe or life-threatening adverse skin reactions. Inflammatory reactions manifesting as maculopapular, papulopustular/acneiform, and eczematous lesions were frequent types of dermatologic toxicities seen with Nibs. Squamous cell carcinoma with keratoacanthoma-like features was associated with a subset of Nibs. Substantial overlap in dermatologic toxicities was found between Nibs. CONCLUSIONS Dermatologic toxicities from Nibs are diverse and may overlap between classes of Nibs. Recognition of the various types of toxicities from Nibs is critical for patient care in the era of "oncodermatology/dermatopathology."
Collapse
Affiliation(s)
- Riyad N H Seervai
- Medical Scientist Training Program, Baylor College of Medicine, Houston, Texas, USA.,Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.,Department of Dermatology, Baylor College of Medicine, Houston, Texas, USA
| | - Woo Cheal Cho
- Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Emily Y Chu
- Department of Dermatology, The University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Mario L Marques-Piubelli
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Debora A Ledesma
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Kristen Richards
- Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Meghan M Heberton
- Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Kelly C Nelson
- Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Priyadharsini Nagarajan
- Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Carlos A Torres-Cabala
- Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Victor G Prieto
- Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Jonathan L Curry
- Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
2
|
Phototoxic and Photoallergic Contact Reactions. Contact Dermatitis 2021. [DOI: 10.1007/978-3-030-36335-2_18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
3
|
|
4
|
Gonçalo M. Phototoxic and Photoallergic Reactions. Contact Dermatitis 2019. [DOI: 10.1007/978-3-319-72451-5_18-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Martinez-Mera C, Capusan TM, Herrero-Moyano M, Urquía Renke A, Steegmann Olmedillas JL, de Argila D. Imatinib-induced pseudoporphyria. Clin Exp Dermatol 2018; 43:463-466. [PMID: 29315788 DOI: 10.1111/ced.13361] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/01/2017] [Indexed: 10/18/2022]
Affiliation(s)
- C Martinez-Mera
- Department of Dermatology, Hospital Universitario de La Princesa, Diego de León 62, Madrid, 28006, Spain
| | - T M Capusan
- Department of Dermatology, Hospital Universitario de La Princesa, Diego de León 62, Madrid, 28006, Spain
| | - M Herrero-Moyano
- Department of Dermatology, Hospital Universitario de La Princesa, Diego de León 62, Madrid, 28006, Spain
| | - A Urquía Renke
- Department of Pathology, Hospital Universitario de La Princesa, Diego de León 62, Madrid, 28006, Spain
| | - J L Steegmann Olmedillas
- Department of Haematology, Hospital Universitario de La Princesa, Diego de León 62, Madrid, 28006, Spain
| | - D de Argila
- Department of Dermatology, Hospital Universitario de La Princesa, Diego de León 62, Madrid, 28006, Spain
| |
Collapse
|
6
|
Vinay K, Yanamandra U, Dogra S, Handa S, Suri V, Kumari S, Khadwal A, Prakash G, Lad D, Varma S, Malhotra P. Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients. Int J Dermatol 2017; 57:332-338. [DOI: 10.1111/ijd.13852] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Revised: 10/02/2017] [Accepted: 11/03/2017] [Indexed: 12/19/2022]
Affiliation(s)
- Keshavamurthy Vinay
- Department of Dermatology, Venereology and Leprology; Postgraduate Institute of Medical Education and Research; Chandigarh India
| | - Uday Yanamandra
- Department of Hematology; Postgraduate Institute of Medical Education and Research; Chandigarh India
| | - Sunil Dogra
- Department of Dermatology, Venereology and Leprology; Postgraduate Institute of Medical Education and Research; Chandigarh India
| | - Sanjeev Handa
- Department of Dermatology, Venereology and Leprology; Postgraduate Institute of Medical Education and Research; Chandigarh India
| | - Vikas Suri
- Department of Hematology; Postgraduate Institute of Medical Education and Research; Chandigarh India
| | - Savita Kumari
- Department of Hematology; Postgraduate Institute of Medical Education and Research; Chandigarh India
| | - Alka Khadwal
- Department of Hematology; Postgraduate Institute of Medical Education and Research; Chandigarh India
| | - Gaurav Prakash
- Department of Hematology; Postgraduate Institute of Medical Education and Research; Chandigarh India
| | - Deepesh Lad
- Department of Hematology; Postgraduate Institute of Medical Education and Research; Chandigarh India
| | - Subhash Varma
- Department of Hematology; Postgraduate Institute of Medical Education and Research; Chandigarh India
| | - Pankaj Malhotra
- Department of Hematology; Postgraduate Institute of Medical Education and Research; Chandigarh India
| |
Collapse
|
7
|
Mahon C, Purvis D, Laughton S, Bradbeer P, Teague L. Imatinib mesylate-induced pseudoporphyria in two children. Pediatr Dermatol 2014; 31:603-7. [PMID: 24920470 DOI: 10.1111/pde.12380] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Imatinib mesylate was the first of several tyrosine kinase inhibitors approved for use in the treatment of a number of human cancers. Adverse cutaneous reactions to imatinib are common. Pseudoporphyria has been infrequently reported in adults undergoing imatinib therapy for chronic myeloid leukemia. We present two children with pseudoporphyria induced by imatinib therapy for hematologic malignancies. In view of the burgeoning use of imatinib in children, physicians should be aware that pseudoporphyria may develop as a consequence of imatinib therapy.
Collapse
Affiliation(s)
- Caroline Mahon
- Department of Paediatric Dermatology, Starship Children's Health, Auckland, New Zealand
| | | | | | | | | |
Collapse
|
8
|
Sanz-Motilva V, Martorell-Calatayud A, Llombart B, Requena C, Serra-Guillén C, Nagore E, Guillén C, Traves V, Sanmartín O. Sunitinib-induced pseudoporphyria. J Eur Acad Dermatol Venereol 2014; 29:1848-50. [PMID: 24813651 DOI: 10.1111/jdv.12539] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- V Sanz-Motilva
- Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
| | | | - B Llombart
- Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
| | - C Requena
- Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
| | - C Serra-Guillén
- Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
| | - E Nagore
- Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
| | - C Guillén
- Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
| | - V Traves
- Department of Pathology, Instituto Valenciano de Oncología, Valencia, Spain
| | - O Sanmartín
- Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
| |
Collapse
|
9
|
Brazzelli V, Grasso V, Borroni G. Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. J Eur Acad Dermatol Venereol 2013; 27:1471-80. [PMID: 23611501 DOI: 10.1111/jdv.12172] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2013] [Accepted: 04/02/2013] [Indexed: 11/27/2022]
Abstract
In the last years, several tyrosine kinase inhibitors (TKIs) have been developed and approved for human cancer treatment. Imatinib mesylate was the first of this novel family of drugs that target cancer-specific molecules and signalling pathways. The appearance of imatinib resistances led to the introduction of second-generation TKIs with higher potency and selectivity, such as dasatinib and nilotinib. However, the range of activity of these agents is not simply directed at tumour cells. Patients and their clinicians are indeed frequently confronted with the cutaneous side-effects associated with the employ of these drugs, which represent the most common non-hematological adverse reactions. For this reason, a systematic dermatological survey of patients receiving these therapies is highly important, and an early and appropriate dermatological treatment is required. In this review, we analyse the clinical and pathological characteristics of the most commonly reported adverse skin events associated with first- and second-generation tyrosine kinase inhibitors, with a particular emphasis on our clinical experience.
Collapse
Affiliation(s)
- V Brazzelli
- Department of Clinical-Surgical, Diagnostic and Paediatric Sciences, Institute of Dermatology, University of Pavia and Foundation IRCCS Policlinico San Matteo, Pavia, Italy
| | | | | |
Collapse
|
10
|
Pérez NO, Esturo SV, Viladomiu EDA, Moreno AJ, Valls AT. Pseudoporphyria induced by imatinib mesylate. Int J Dermatol 2013; 53:e143-4. [DOI: 10.1111/j.1365-4632.2012.05574.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Markova A, Lester J, Wang J, Robinson-Bostom L. Diagnosis of common dermopathies in dialysis patients: a review and update. Semin Dial 2013; 25:408-18. [PMID: 22809004 DOI: 10.1111/j.1525-139x.2012.01109.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Cutaneous abnormalities in patients with end-stage renal disease (ESRD) receiving hemodialysis or peritoneal dialysis may demonstrate signs of their underlying condition or reveal associated disease entities. While a thorough examination of the scalp, skin, mucosa, and nails is integral to establishing a diagnosis, certain conditions will resolve only with dialysis or improvement of their renal disease and others may not require or respond to treatment. Half and half nails, pruritus, xerosis, and cutaneous hyperpigmentation are common manifestations in ESRD. With hemodialysis, uremic frost is no longer prevalent in ESRD patients and ecchymoses have decreased in incidence. Acquired perforating dermatoses are seen in over one-tenth of hemodialysis patients. Metastatic calcinosis cutis and calciphylaxis are both rarely reported, although the latter is seen almost exclusively in the setting of hemodialysis. Diagnosis of nephrogenic systemic fibrosis has historically been challenging; as such, new diagnostic criteria have been proposed. Blood porphyrin profiles are needed to differentiate between porphyria cutanea tarda and pseudoporphyria. We will review and provide an update on the aforementioned common cutaneous manifestations of ESRD in patients receiving dialysis.
Collapse
Affiliation(s)
- Alina Markova
- Department of Dermatology, Alpert Medical School of Brown University, Providence, Rhode Island 02903, USA
| | | | | | | |
Collapse
|